KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Investing Activities (2016 - 2025)

Arbutus Biopharma's Cash from Investing Activities history spans 13 years, with the latest figure at -$10.0 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 16.41% year-over-year to -$10.0 million; the TTM value through Sep 2025 reached $30.4 million, down 4.44%, while the annual FY2024 figure was $22.9 million, 54.8% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$10.0 million at Arbutus Biopharma, down from $15.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $22.2 million in Q4 2023 and bottomed at -$60.1 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is $10.4 million (2023), against an average of $160105.3.
  • The largest annual shift saw Cash from Investing Activities soared 858.89% in 2021 before it tumbled 429.6% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$8.1 million in 2021, then surged by 256.16% to $12.7 million in 2022, then soared by 75.25% to $22.2 million in 2023, then plummeted by 39.66% to $13.4 million in 2024, then tumbled by 174.71% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Cash from Investing Activities are -$10.0 million (Q3 2025), $15.6 million (Q2 2025), and $11.3 million (Q1 2025).